|
Real-world assessment of practice efficiency with the introduction of subcutaneous rituximab. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech; Roche |
|
|
Stock and Other Ownership Interests - Merck |
Honoraria - Bayer; Genentech; GlaxoSmithKline; Janssen; Pharmacyclics; Roche; Seagen |
Consulting or Advisory Role - Bayer; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Teva |
Research Funding - Bayer; Genentech; GlaxoSmithKline; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen |
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen |